SCHEMBL861291

SCHEMBL861291

CC(C)C(O)c1ccccc1C(O)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.46
GABRB2 P47870 2/20 0.46
LMNA P02545 2/20 0.42
HIF1A Q16665 2/20 0.42
ADRA2C P18825 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ADRA2A P08913 1/20 0.42
PDE2A O00408 1/20 0.42
TSHR P16473 3/20 0.42
CYP3A4 P08684 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
FAAH O00519 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CYP1A2 P05177 1/20 0.42
HPGD P15428 1/20 0.42
GABRB1 P18505 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5101388 1.00 GABRA1 (0.46) GABRA1GABRB2LMNAHIF1AADRA2C
SCHEMBL6055154 0.92 GABRA1 (0.52) GABRA1GABRB2LMNAHIF1AADRA2C
SCHEMBL6055139 0.87 ESR1 (0.50) GABRA1GABRB2LMNAHIF1AADRA2C
SCHEMBL19757657 0.87 ESR1 (0.50) GABRA1GABRB2LMNAHIF1AADRA2C
SCHEMBL9157882 0.85 GABRA1 (0.62) GABRA1GABRB2LMNAHIF1AADRA2C
SCHEMBL9667214 0.85 PDE2A (0.50) GABRA1GABRB2HIF1APDE2ACYP3A4
SCHEMBL17407623 0.83 ADRB2 (0.52) GABRA1GABRB2LMNAHIF1AKDM4E
SCHEMBL31521478 0.83 ADRB2 (0.52) GABRA1GABRB2LMNAHIF1AKDM4E
SCHEMBL3551469 0.83 HTT (0.43) GABRA1GABRB2LMNAHIF1AADRA2C
SCHEMBL14873239 0.83 ADRB2 (0.52) GABRA1GABRB2LMNAHIF1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8142909-B2 Blue phosphorescent imidazophenanthridine materials UNIVERSAL DISPLAY CORPORATION (US) 2012-03-27 US disclosed
US-8142909-B2 Blue phosphorescent imidazophenanthridine materials UNIVERSAL DISPLAY CORPORATION (US) 2012-03-27 US disclosed
WO-2008156879-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2008-12-24 WO disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS UNIVERSAL DISPLAY CORPORATION 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080297033-A1 BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS IK, CRY1, MAP1LC3C GABRA1 432/4885GABRB2 1574/4885LMNA 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.